Therapeutic vaccination with an interleukin-2-interferon-γ-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: A phase I/II trial

Human Gene Therapy

Volumn 20, Issue 12, 2009, Pages 1641-1651

  Brill, Thomas H ^a   Kübler, Hubert R ^a   Pohla, Heike ^b,c   Buchner, Alexander ^b   Fend, Falko ^a,d   Schuster, Tibor ^a   Van Randenborgh, Heiner ^a   Paul, Roger ^a   Kummer, Tania ^a   Plank, Christian ^a   Eisele, Bernd ^e   Breul, Jürgen ^a   Hartung, Rudolf ^a   Schendel, Dolores J ^c   Gansbacher, Bernd ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e Vakzine Projekt Management   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; TUMOR VACCINE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE PAIN; BONE SCINTISCANNING; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CELL COUNT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPESTHESIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAIN; PARESTHESIA; PROSTATE CANCER; RHINOPHARYNGITIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TUMOR GROWTH; TUMOR IMMUNITY; VERTIGO; VOMITING;

AGED; AGED, 80 AND OVER; CANCER VACCINES; CASTRATION; CELL LINE, TUMOR; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; VACCINATION;

EID: 74549148318     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.101     Document Type: Article

References (69)

1. Abbod, M.F., Catto, J.W., Linkens, D.A., and Hamdy, F.C. (2007). Application of artificial intelligence to the management of urological cancer. J. Urol. 178, 1150-1156.
2. Arlen, P.M., Bianco, F., Dahut, W.L., D'Amico, A., Figg, W.D., Freedland, S.J., Gulley, J.L., Kantoff, P.W., Kattan, M.W., Lee, A., Regan, M.M., and Sartor, O.; Prostate Specific Antigen Working Group. (2008). Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J. Urol. 179, 2181-2185.
3. Atzpodien, J., Kirchner, H., Illiger, H.J., Metzner, B., Ukena, D., Schott, H., Funke, P.J., Gramatzki, M., von Jü rgenson, S., Wandert, T., Patzelt, T., and Reitz, M. (2001). IL-2 in combination with IFN-a and 5-FU versus tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130-1136.
4. Bander, N.H., Yao, D., Liu, H., Chen, Y.-T., Steiner, M., Zuccaro, W., and Moy, P. (1997). MHC class I and II expression in prostate carcinoma and modulation by interferon-a and-g. Prostate 33, 233-239.
5. Berthold, D.R., Pond, G.R., Soban, F., de Wit, R., Eisenberger, M., and Tannock, I.F. (2008). Docetaxel plus prednisone or mitox-antrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 Study. J. Clin. Oncol. 26, 242-245.
6. Brawer, M.K. (2006). Hormonal therapy for prostate cancer. Rev. Urol. 8(Suppl. 2), S35-S47.
7. Brill, T.H., Kuebler, H.R., von Randenborgh, H., Fend, F., Pohla, H., Breul, J., Hartung, R., Paul, R., Schendel, D.J., and Gans-bacher, B. (2007). Allogeneic retrovirally transduced, IL-2-and IFN-g-secreting cancer cell vaccine in patients with hormone refractory prostate cancer: A phase I clinical trial. J. Gene Med. 9, 547-560.
8. Correale, P., Walmsley, K., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K.Y. (1998). Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol. 161, 3186-3194.
9. Dannull, J., Diener, P.A., Prikler, L., Furstenberger, G., Cerny, T., Schmid, U., Ackermann, D.K., and Groettrup, M. (2000). Prostate stem cell antigen is a promising candidate for im-munotherapy of advanced prostate cancer. Cancer Res. 60, 5522-5528.
10. Dreicer, R., Stadler, W.M., Ahmann, F.R., Whiteside, T., Bizouarne, N., Acres, B., Limacher, J.M., Squiban, P., and Pantuck, A. (2008). MVA-MUC-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest. New Drugs 27, 379-386.
11. Finn, O.J. (2008). Cancer immunology. N. Engl. J. Med. 358, 2704-2715.
12. Freedland, S.J., Humphreys, E.B., and Mangold, L.A. (2007). Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J. Clin. Oncol. 25, 1765-1771.
13. Gansbacher, B., Bannerji, R., Daniels, B., Daniels, B., Cronin, K., and Gilboa, E. (1990a). Retroviral vector-mediated g interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50, 7820-7825.
14. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. (1990b). Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1724.
15. Halabi, S., Small, E.J., Kantoff, P.W., Kattan, M.W., Kaplan, E.B., Dawson, N.A., Levine, E.G., Blumenstein, B.A., and Vo-gelzang, N.J. (2003). Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21, 1232-1237.
16. Higano, C.S., Corman, J.M., Smith, D.C., Centeno, A.S., Steidle, C.P., Gittleman, M., Simons, J.S., Sacks, N., Aimi, J., and Small, E.J. (2008). Phase 1=2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113, 975-984.
17. Higano, C.S., Schellhammer, P.F., Small, E.J., Burch, P.A., Neu-munaitis, J., Yuh, L., Provost, N., and Frohlich, M.W. (2009). Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679.
18. Hsueh, E.C., Essner, R., Foshag, L.J., Ollila, D.W., Gammon, G., O'Day, S.J., Boasberg, P.D., Stern, S.L., Ye, X., and Morton, D.L. (2002). Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 20, 4549-4554.
19. + regulatory T cells rescue scurfy mice. Eur. J. Immunol. 38, 1814-1821.
20. Jäger, E., Chen, Y.-T., Drijfhout, J.W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L.J., and Knuth, A. (1998). Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265-270.
21. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M.J. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96.
22. Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, W., von Wietersheim, J., and Doehn, C. (2004). Adjuvant autolo-gous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363, 594-599.
23. Kawashima, I., Hudson, S.J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., and Celis, E. (1998). The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59, 1-14.
24. Kessler, J.H., Beekman, N.J., Bres-Vloemans, S.A., Verdijk, P., van Veelen, P.A., Kloosterman-Joosten, A.M., Vissers, D.C., ten Bosch, G.J., Kester, M.G., Sijts, A., Wouter Drijfhout, J., Os-sendorp, F., Offringa, R., and Melief, C.J. (2001). Efficient identification of novel HLA-A*0201- presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193, 73-88.
25. + T cells in prostate cancer patients. Int. J. Cancer 102, 390-397.
26. Kim, C.J., Taubenberger, J.K., Simonis, T.B., White, D.E., Rosenberg, S.A., and Marincola, F.M. (1996). Combination therapy with interferon-g and interleukin-2 for the treatment of metastatic melanoma. J. Immunother. Emphasis Tumor Immunol. 19, 50-58.
27. Krogh, A. (2008). What are artificial neural networks? Nat. Biotechnol. 26, 195-197.
28. Lee, H.M., Timme, T.L., and Thompsen, T.C. (2000). Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells. Cancer Res. 60, 1927-1933.
29. Lu, J., and Celis, E. (2002). Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 62, 5807-5812.
30. Machlenkin, A., Paz, A., Bar Haim, E., Goldberger, O., Finkel, E., Tirosh, B., Volovitz, I., Vadai, E., Lugassy, G., Cytron, S., Lemonnier, F., Tzehoval, E., and Eisenbach, L. (2005). Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res. 65, 6435-6442.
31. Margolin, K.A., Doroshow, J.H., Akman, S.A., Leong, L.A., Morgan, R.J., Raschko, J., Somlo, G., Mills, B., Goldberg, D., and Sniecinski, I. (1992). Phase I trial of interleukin-2 plus g-interferon. J. Immunother. 11, 50-55.
32. - prostate cancer patients. Prostate 60, 205-213.
33. Michael, A., Ball, G., Quatan, N., Wushishi, F., Russell, N., Whelan, J., Chakraborty, P., Leader, D., Whelan, M., and Pandha, H. (2005). Delayed disease progression after alloge-neic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. 11, 4469-4478.
34. Negrier, S., Caty, A., Lesimple, T., Douillard, J.-Y., Escudier, B., Rossi, J.-F., Viens, P., and Gomez, F.; Groupe Francais d'Im-munotherapie, Federation Nationale des Centres de Lutte contre le Cancer. (2000). Treatment of patients with meta-static renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J. Clin. Oncol. 18, 4009-4015.
35. Nussbaum, A.K., Kuttler, C., Hadeler, K.P., Rammensee, H.G., and Schild, H. (2001). PAProC: A prediction algorithm for proteasomal cleavages available on the WWW. Im-munogenetics 53, 87-94.
36. Old, L.J. (2008). Cancer vaccines: An overview. Cancer Immun. 8(Suppl. 1), S1-S4.
37. Oudard, S., Banu, E., Scotte, F., Banu, A., Medioni, J., Beuzeboc, P., Joly, F., Ferrero, J.M., Goldwasser, F., and Andrieu, J.M. (2007). Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann. Oncol. 18, 1828-1833.
38. Palmer, K., Moore, J., Everard, M., Harris, J.D., Rodgers, S., Rees, R.C., Murray, A.K., Mascari, R., Kirkwood, J., Riches, P.G., Fisher, C., Thomas, J.M., Harries, M., Johnston, S.R., Collins, M.K., and Gore, M.E. (1999). Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. 10, 1261-1268.
39. Pandha, H.S., Stockwin, L.H., Eaton, J., Clarke, I.A., Dalgleish, A.G., Todryk, S.M., and Blair, G.E. (2003). Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: Implications for gene therapy strategies. Prostate Cancer Prostatic Dis. 6, 6-11.
40. + cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36, 129-138.
41. Petrylak, D.P. (2007). New paradigms for advanced prostate cancer. Rev. Urol. 9(Suppl. 2), S3-S12.
42. Propper, D.J., Chao, D., Braybrooke, J.P., Bahl, P., Thavasu, P., Balkwill, F., Turley, H., Dobbs, N., Gatter, K., Talbot, D.C., Harris, A.L., and Ganesan, T.S. (2003). Low-dose IFN-g induces tumor MHC expression in metastatic malignant melanoma. Clin. Cancer Res. 9, 84-92.
43. Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A., and Stevanovic, S. (1999). SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219
44. Redman, B.G., Flaherty, L., Chou, T.H., Al-Katib, A., Kraut, M., Martino, S., Chen, B., Kaplan, J., and Valdivieso, M. (1990). A phase I trial of recombinant interleukin-2 combined with re-combinant interferon-g in patients with cancer. J. Clin. Oncol. 8, 1269-1276.
45. Rosenberg, S.A., Blaese, R.M., Brenner, M.K., Deisseroth, A.B., Ledley, F.D., Lotze, M.T., Wilson, J.M., Nabel, G.J., Cornetta, K., Economou, J.S., Freeman, S.M., Riddell, S.R., Oldfield, E., Gansbacher, B., Dunbar, C., Walker, R.E., Schuening, F.G., Roth, J.A., Crystal, R.G., Welsh, M.J., Culver, K., Heslop, H.E., Simons, J., Wilmott, R.W., and Habib, N.A. (1999). Human gene marker=therapy clinical protocols. Hum. Gene Ther. 10, 3067-3123.
46. Rosenberg, S.A., Blaese, R.M., Brenner, M.K., Deisseroth, A.B., Ledley, F.D., Lotze, M.T., Wilson, J.M., Nabel, G.J., Cornetta, K., Economou, J.S., Freeman, S.M., Riddell, S.R., Brenner, M., Oldfield, E., Gansbacher, B., Dunbar, C., Walker, R.E., Schu-ening, F.G., Roth, J.A., Crystal, R.G., Welsh, M.J., Culver, K., Heslop, H.E., Simons, J., Wilmott, R.W., Boucher, R.C., Siegler, H.F., Barranger, J.A., Karlsson, S., Kohn, D., Galpin, J.E., Raffel, C., Hesdorffer, C., Ilan, J., Cassileth, P., O'Shaughnessy, J., Kun, L.E., Das, T.K., Wong-Staal, F., Sobol, R.E., Haubrich, R., Sznol, M., Rubin, J., Sorcher, E.J., Rosenblatt, J., Walker, R., Brigham, K., Vogelzang, N., Hersh, E., Curiel, D., Evans, C.H., Freedman, R., Liu, J., Simons, J., Flotte, T.R., and Holt, J. (2000). Human gene marker=therapy clinical protocols. Hum. Gene Ther. 11, 919-979.
47. Rosenthal, F., Cronin, K., Bannerji, R., Golde, D., and Gansba-cher, B. (1994). Synergistic induction of cytotoxic effector cells by tumor cells transduced with a retroviral vector carrying both the IL-2 and IFN-g cDNAs. Blood 83, 1289-1298.
48. Rumelhart, D.E., Hinton, G.E., and Williams, R.J. (1986). Learning internal representations by error propagation. In Parallel Distributed Processing: Explorations in the Microstructure of Cognition. Rumelhart, D.E., and McClelland, J., eds. (MIT Press, Cambridge, MA) pp. 318-362.
49. Salgaller, M.L., Lodge, P.A., McLean, J.G., Tjoa, B.A., Loftus, D.J., Ragde, H., Kenny, G.M., Rogers, M., Boynton, A.L., and Murphy, G.P. (1998). Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35, 144-151.
50. Schaue, D., Comin-Anduiy, B., Ribas, A., Zhang, L., Goodglick, L., Sayre, J.W., Debucquoy, A., Haustermans, K., and McBride, W.H. (2008). T-cell responses to surviving in cancer patients undergoing radiation therapy. Clin. Cancer Res. 14, 4883-4890.
51. Scher, H.I., Kelly, W.K., Zhang, Z.-F., Ouyang, P., Sun, M., Schwartz, M., Ding, C., Wang, W., Horak, I.D., and Kremer, A.B. (1999). Post-therapy serum prostate specific antigen level and survival in patients with androgen-independent prostate cancer. J. Natl. Cancer Inst. 91, 244-251.
52. Scher, H.I., Morris, M.J., Kelly, W.K., Schwartz, L.H., and Heller, G. (2005). Prostate cancer clinical trial end points: "RECIST"-ing a step backwards. Clin. Cancer Res. 11, 5223-5232.
53. Scher, H.I., Halabi, S., Tannock, I., Morris, M., Sternberg, C.N., Carducci, M.A., Eisenberger, M.A., Higano, C., Bubbley G.J., Dreicer, R., Petrylak, D., Kantoff, P., Basch, E., Kelly, W.K., Figg, W.D., Small, E.J., Beer, T.M., Wilding, G., Martin, A., and Hussain, M. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159.
54. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60, 4845-4849.
55. Schröder, F.H., Roach, M., and Scardino, P. (2008). Management of prostate cancer. N. Engl. J. Med. 359, 2605-2609.
56. Simons, J.W., Mikhak, B., Chang, J.F., DeMarzo, A.M., Carducci, M.A., Lim, M., Weber, C.E., Baccala, A.A., Goemann, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H.B., Piantadosi, S., Marshall, F.F., and Nelson, W.G. (1999). Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160-5168.
57. Simons, J.W., Carducci, M.A., Mikhak, B., Lim, M., Biedrzycki, B., Borellini, F., Clift, S.M., Hege, K.M., Ando, D.G., Pianta-dosi, S., Mulligan, R., and Nelson, W.G. (2006). Phase I=II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res. 12, 3394-3401.
58. Small, E.J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M.V., and Valone, F.H. (2000). Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903.
59. Small, E.J., Schellhammer, P.F., Higano, C.S., Redfern, C.H., Nemunaitis, J.J., Valone, F.H., Verjee, S.S., Jones, L.A., and Hershberg, R.M. (2006). Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094.
60. Sonpavde, G., Hutson, T.E., and Berry, W.R. (2006). Hormone refractory prostate cancer: Management and advances. Cancer Treat. Rev. 32, 90-100. (Pubitemid 43362230)
61. Thall, P.F., Logothetis, C., Pagliaro, L.C., Wen, S., Brown, M.A., Williams, D., and Millikan, R.E. (2007). Adaptive therapy for androgen-independent prostate cancer: A randomized selection trial of four regimens. J. Natl. Cancer Inst. 99, 1613-1622.
62. Tomioka, S., Shimbo, M., Amiya, Y., Nakatsu, H., Murakami, S., Shimazaki, J. (2007). Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: Analysis on 56 cases of cancer-specific death. Int. J. Urol. 14, 123-127.
63. Trojan, A., Witzens, M., Schultze, J.L., Vonderheide, R.H., Harig, S., Krackhardt, A.M., Stahel, R.A., and Gribben, J.G. (2001). Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res. 61, 4761-4765.
64. Webster, W.S., Small, E.J., Rini, B.I., and Kwon, E.D. (2005). Prostate cancer immunology: Biology, therapeutics, and challenges. J. Clin. Oncol. 23, 8262-8269.
65. Weiner, L.M. (2008). Cancer immunotherapy: The endgame begins. N. Engl. J. Med. 358, 2664-2665.
66. Weiner, L.M., Padavic-Shaller, K., Kitson, J., Watts, P., Krigel, R.L., and Litwin, S. (1991). Phase I evaluation of combination therapy with interleukin 2 and g-interferon. Cancer Res. 51, 3910-3918.
67. + prostate cancer patients. Prostate 62, 233-242.
68. + regulatory T cells induced by IL-2 and TGF-b are resistant to TH17 conversion by IL-6. J. Immunol. 180, 7112-7116.
69. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Andre, F., Tesniere, A., and Kroemer, G. (2008). The anticancer immune response: Indispensable for therapeutic success? J. Clin. Invest. 118, 1991-2001.